Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI PET in Heart Failure
NCT07083011Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-FAPI in heart failure with preserved ejection fraction (HFpEF), cardiac sarcoidosis (CS), sponsored by Mayo Clinic. Started Nov 2025; status: recruiting.
02
Drugs
68Ga-FAPI
03
Conditions
heart failure with preserved ejection fraction (HFpEF)cardiac sarcoidosis (CS)
Beyond the preview
Go deeper on NCT07083011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083011.